Antiviral therapy reduces HCC and cirrhosis risk in Chinese chronic hepatitis B patients with mildly elevated ALT

Key Points

• Antiviral therapy significantly reduces the risk of hepatocellular carcinoma (HCC) and cirrhosis related to chronic hepatitis B.
• Patients with mildly elevated ALT levels experienced a notable decrease in HCC risk post-therapy.
• Observational analysis of Chinese patients highlights the therapeutic potential of intervention against chronic hepatitis B.
• Long-term antiviral treatment may enable better health outcomes in chronic hepatitis B patients, requiring further study.